Skip to content
Menu
Eclipse Regenesis
  • Home
  • About
    • Short Bowel Syndrome
    • Testimonials
    • Publications
  • Device
  • Resources
  • Contact Us
Close Menu
National Science Foundation Grant Recipient
April 2, 2021

NSF Small Business Innovation Research (SBIR) Grant Award

Eclipse Regenesis, developer of the first restorative therapy to address Short Bowel Syndrome (SBS), has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant of $256,000 to develop a minimally-invasive version of its Eclipse XL1 System™ for pediatric and adult patients with Short Bowel Syndrome.

Short Bowel Syndrome is a devastating condition where the small intestine is too short to absorb sufficient nutrients to sustain a patient. Current chronic therapies include intravenous nutrition, medication and intestinal surgery, which have low success rates and high five-year costs of up to $1.6 million per patient. Preclinical studies have shown that the Eclipse XL1 System promotes a process known as distraction enterogenesis in a treatment that is designed to produce new, fully functional intestine, as a way to restore natural nutrient absorption. The Eclipse XL1’s unique mechanism of action has been published in more than 20 peer reviewed publications.

“We are gratified that the National Science Foundation has recognized our novel concept that has the potential to improve and extend the lives of children and adults who are suffering with SBS,” said Eclipse Regenesis CEO Andre Bessette. “We look forward to utilizing the funds to develop a less invasive, endoscopic system that will be more accessible and improve upon the patient experience.”

“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”

Once a small business is awarded a Phase I SBIR/STTR grant (up to $256,000), it becomes eligible to apply for a Phase II grant (up to $1,000,000). All proposals submitted to the NSF SBIR/STTR program, also known as America’s Seed Fund powered by NSF, undergo a rigorous merit-based review process. To learn more about America’s Seed Fund powered by NSF, visit: https://seedfund.nsf.gov/

More About Short Bowel Syndrome

Short Bowel Syndrome results from the surgical removal of a large portion of the small intestine due to a congenital or acquired defect. It is a devastating condition where patients struggle to absorb life-sustaining nutrients from their diet. Common causes in pediatrics are necrotizing enterocolitis (NEC) and birth defects such as gastroschisis, volvulus, Hirschsprung’s disease, intestinal atresia, and other congenital defects. The cost of care for each patient is more than $1.6 million over five years and costs to the U.S. healthcare system are upwards of $3 billion each year.
 

About the National Science Foundation’s Small Business Programs

America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.75 million to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.1 billion that supports fundamental research and education across all fields of science and engineering.

About Eclipse Regenesis

Eclipse Regenesis, Inc. is a development-stage medical device company focused on harnessing the body’s own tissue regeneration capabilities to treat important diseases. Its flagship product, the Eclipse XL1 System, utilizes distraction enterogenesis in a treatment designed to mechanically stimulate the body to produce new, fully-functional intestinal tissue to address Short Bowel Syndrome (SBS). With the support of more than 15 years of scientific research and the participation of world renowned SBS thought leaders, the Eclipse Regenesis team is passionate about pioneering a restorative therapy for a devastating condition that has no cure today. The Eclipse XL-1 system is under development and not available for clinical use at this time.

Back To Top
Eclipse Regenesis
  • Home
  • About
  • Device
  • Resources
  • Contact
  • Share Your Story
  • Privacy Policy
  • Terms Of Use

© Copyright Eclipse Regenesis 2021. All rights reserved.

Website provided by: Jib Sheet Partners – Patient-Centered Branding and Marketing For Women’s And Pediatric Healthcare Organizations

*The Eclipse XL1 is currently under development and not available for clinical use.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie SettingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Advertisement

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

SAVE & ACCEPT